Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Ken Herrmann

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9662-7259; OpenAlex author ID A5006830341, A5104053820. Sources: OpenAlex.

Their work

Papers
8 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
35
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 3 papers · 2024: none · 2025: 1 paper

Papers 8

  1. The Value of FAPI PET/CT in Cholangiocarcinoma and Pancreatic Cancer: An Update. Last author DOI 10.1053/j.semnuclmed.2025.06.011↗
  2. Gallium-68-labeled fibroblast activation protein inhibitor-46 PET in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma: A phas… Co-author DOI 10.1371/journal.pone.0294564↗
  3. 68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-FAPI PET Observational Trial. Co-author DOI 10.2967/jnumed.122.264827↗
  4. Advancing Clinical Trial Innovation in Pancreatic Cancer: A Conversation Between Diane Simeone, Ken Herrmann, and Johannes Czernin. First author DOI 10.2967/jnumed.123.265432↗
  5. 18F-FDG PET/CT Imaging Biomarkers for Early and Late Evaluation of Response to First-Line Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.2967/jnumed.121.261952↗
  6. European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Pancreatic Cancer. Co-author DOI 10.1016/j.ctrv.2021.102208↗
  7. 18F-fluorothymidine PET for predicting survival in patients with resectable pancreatic cancer. Co-author DOI 10.18632/oncotarget.24176↗
  8. Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Can… First author DOI 10.1159/000367966↗

Closest collaborators

The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wolfgang P. Fendler · 2 shared papers, 2023–2025 · strength 0.51
  2. Kim Magaly Pabst · 2 shared papers, 2023–2025 · strength 0.51
  3. Diane M. Simeone · 2 shared papers, 2023 · strength 0.46
  4. Johannes Czernin · 2 shared papers, 2022–2023 · strength 0.45
  5. Jens Thomas Siveke · 2 shared papers, 2018–2023 · strength 0.24
  6. Hongli Chen · 1 shared paper, 2023 · strength 0.16
  7. Aashna Karbhari · 1 shared paper, 2023 · strength 0.16
  8. Mark Joseph Truty · 1 shared paper, 2023 · strength 0.16
  9. Ajit Harishkumar Goenka · 1 shared paper, 2023 · strength 0.16
  10. Céline Lugnier · 1 shared paper, 2023 · strength 0.15
  11. Waldemar H. Uhl · 1 shared paper, 2023 · strength 0.15
  12. Lukas Kessler · 1 shared paper, 2023 · strength 0.15
  13. David P. Witte · 1 shared paper, 2023 · strength 0.15
  14. Anke Reinacher‐Schick · 1 shared paper, 2023 · strength 0.15
  15. Timothy R. Donahue · 1 shared paper, 2022 · strength 0.14
  16. Zev A. Wainberg · 1 shared paper, 2022 · strength 0.14
  17. Matthias Benz · 1 shared paper, 2022 · strength 0.14
  18. Mark D. Girgis · 1 shared paper, 2022 · strength 0.14
  19. Jérémie Calais · 1 shared paper, 2022 · strength 0.14
  20. Marc Zins · 1 shared paper, 2021 · strength 0.10
  21. Cindy Neuzillet · 1 shared paper, 2021 · strength 0.10
  22. Philip M. Poortmans · 1 shared paper, 2021 · strength 0.10
  23. Sorin Traian Barbu · 1 shared paper, 2021 · strength 0.10
  24. Stefano Partelli · 1 shared paper, 2021 · strength 0.10
  25. Hanna E. Seppänen · 1 shared paper, 2021 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.